Evidence map›Paper›PMID 42246053›Full record

ReviewFrontiers in neurology

The cumulative impact of seizures: the science underlying how seizures beget seizures.

Richard M Gustin, Taha Gholipour, Jurriaan M Peters

Abstract readReview
In one paragraph

Review in Frontiers in neurology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Richard M GustinNeurelis, Inc., San Diego, CA, United States.
Taha GholipourDepartment of Neurosciences, University of California San Diego, La Jolla, CA, United States.
Jurriaan M PetersDepartment of Neurology, Division of Epilepsy and Neurophysiology, Boston Children's Hospital and Harvard Medical School, Boston, MA, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Seizures are symptoms of epilepsy but spontaneous seizure recurrence can also be considered a biomarker of disease progression. The temporary imbalance between excitatory and inhibitory drive that culminates in a hyperexcitable, hypersynchronous state clinically observed as seizure, initiates an insidious cascade of neurochemical, structural, genetic, epigenetic, and neuroinflammatory processes that increases seizure frequency, duration, and severity. As seizure activity increases, the hyperexcitable and hypersynchronous states entrain neuronal networks, leading to a further reduction in seizure threshold and further increases in seizure frequency, duration, and severity over time. The pathological circuitry generated and sustained by epileptic events not only drive hyperexcitable states within the seizure circuit but also can affect wider network connections. These effects lead to altered network physiology, which is associated with neuropsychiatric comorbidities, such as cognitive decline and psychiatric disorders, and can impact the operation of other organ systems. Here, we review the current understanding of how seizures can hijack normal brain function and set off a cascade of pathobiological events that support continued seizure activity and epilepsy progression. Understanding the neurobiology of seizure progression is fundamental to building comprehensive treatment strategies and developing new pharmacotherapies that aim to retrain seizure circuitry, with the goal of reducing overall seizure burden, improving quality of life, and limiting disease progression.

Indexed as

drug-resistant epilepsyepilepsy treatmenthyperexcitabilityquality of lifeseizure progressionseizure timeline

Identifiers

PMID42246053
PMCPMC13232767

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.